{"nctId":"NCT00664859","briefTitle":"12-Month, Open-Label, Extension Study of LCP-AtorFen in Dyslipidemia","startDateStruct":{"date":"2007-10"},"conditions":["Dyslipidemia"],"count":140,"armGroups":[{"label":"Single","type":"EXPERIMENTAL","interventionNames":["Drug: LCP-AtorFen"]}],"interventions":[{"name":"LCP-AtorFen","otherNames":["atorvastatin and fenofibrate combination therapy"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n1. Subject has successfully completed the double-blind study (LCP-AtorFen-2001; NCT00504829).\n2. Subject has confirmed his or her willingness to participate in this study after being informed of all aspects of the study by voluntarily signing and dating an informed consent form in accordance with Good Clinical Practice (GCP).\n\nExclusion Criteria:\n\n1. Study drug compliance \\<70% in the double-blind study.\n2. Any ongoing serious adverse event, or any ongoing non-serious moderate or severe adverse event from the double-blind study that is rated as possibly, probably or definitely related to study drug.\n3. Resting blood pressure \\>/=160 mm Hg systolic and/or \\>/=100 mm Hg diastolic.\n4. Symptoms of unexplained muscle pain, tenderness or weakness (i.e., signs indicative of possible myopathy), or any diagnosis of myopathy or rhabdomyolysis.\n5. Any clinically significant change in physical exam or electrocardiogram from Visit 2 to Visit 6 of the double-blind study.\n6. Any clinically significant change from Visit 1 to Visit 6 of the double-blind study in medical history including, but not limited to: a diagnosis of insulin-dependent diabetes mellitus (DM); poorly controlled DM; poorly controlled hypertension; significant renal, pulmonary, hepatic, biliary, or gastrointestinal disease; cancer (except non-melanoma skin cancer); and epilepsy.\n7. Unwilling to abstain from medications, supplements, ingredients and herbal therapies that were excluded in the double-blind study and continue to be excluded in the open-label study.\n8. Women who are pregnant, planning to be pregnant during the study period, lactating, or women of childbearing potential (not surgically sterilized between menarche and menopause) who are not using a medically approved method of contraception.\n9. Other exclusion conditions might apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Non-HDL Cholesterol, HDL Cholesterol, TG Levels From Baseline to End of Treatment","description":"Mean percent changes in non-HDL cholesterol, HDL cholesterol, TG levels from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12 of DB study) to end of treatment (Week 52)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-48.2","spread":"13.58"},{"groupId":"OG001","value":"-43.6","spread":"18.18"},{"groupId":"OG002","value":"-42.0","spread":"20.49"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.6","spread":"22.39"},{"groupId":"OG001","value":"2.8","spread":"33.67"},{"groupId":"OG002","value":"-29.6","spread":"26.92"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.1","spread":"25.31"},{"groupId":"OG001","value":"-51.2","spread":"23.23"},{"groupId":"OG002","value":"-42.1","spread":"29.96"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.4","spread":"65.36"},{"groupId":"OG001","value":"-19.1","spread":"40.42"},{"groupId":"OG002","value":"-5.2","spread":"53.27"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"22.1","spread":"21.7"},{"groupId":"OG001","value":"16.3","spread":"18.67"},{"groupId":"OG002","value":"17.5","spread":"20.21"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"16.9"},{"groupId":"OG001","value":"10.1","spread":"17.77"},{"groupId":"OG002","value":"-2.4","spread":"15.4"}]}]}]},{"type":"SECONDARY","title":"Change in LDL Cholesterol, VLDL, Total Cholesterol, Apo A-1, and Apo B From Baseline to End of Treatment","description":"Mean percent changes in LDL cholesterol, VLDL, total cholesterol, Apo A-1, and Apo B from the double-blind (DB) baseline (Week 0) to end-of-treatment (Week 52), and from the open-label (OL) baseline (week 12) to end-of-treatment (Week 52)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.8","spread":"15.92"},{"groupId":"OG001","value":"-39.3","spread":"20.04"},{"groupId":"OG002","value":"-40.9","spread":"22.0"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","spread":"25.09"},{"groupId":"OG001","value":"14","spread":"36.29"},{"groupId":"OG002","value":"-33.6","spread":"24.26"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-53.6","spread":"23.98"},{"groupId":"OG001","value":"-51.1","spread":"23.07"},{"groupId":"OG002","value":"-42.0","spread":"29.94"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"12.7","spread":"69.42"},{"groupId":"OG001","value":"-18.7","spread":"39.97"},{"groupId":"OG002","value":"-5.5","spread":"51.98"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-36.5","spread":"11.07"},{"groupId":"OG001","value":"-33.8","spread":"14.6"},{"groupId":"OG002","value":"-32.8","spread":"16.08"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","spread":"12.95"},{"groupId":"OG001","value":"4.6","spread":"24.54"},{"groupId":"OG002","value":"-24.4","spread":"19.04"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.2","spread":"13.21"},{"groupId":"OG001","value":"1.0","spread":"9.88"},{"groupId":"OG002","value":"0.4","spread":"12.5"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.4","spread":"8.11"},{"groupId":"OG001","value":"1.9","spread":"13.62"},{"groupId":"OG002","value":"-5.1","spread":"11.36"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"-42.4","spread":"11.85"},{"groupId":"OG001","value":"-38.9","spread":"16.26"},{"groupId":"OG002","value":"-36.8","spread":"18.81"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3.1","spread":"17.69"},{"groupId":"OG001","value":"-1.5","spread":"25.14"},{"groupId":"OG002","value":"-25.5","spread":"21.59"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":3,"n":51},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Blood glucose increased","Muscle spasms"]}}}